Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium and Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (N08CB/Alliance)
      QxMD      Google Scholar   
Citation:
J Clin Oncol vol 32 (10) 997-1005
Year:
2014
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
3
Parents:
959  
Children:
None
Program:
CCP
Primary Committee:
Symptom Inter
Sec. Committees:
   
Pharmas:
 
Grants:
CA33601, N01 CA035431, U10 CA035269, CA-37404, U10 CA031946, CA-63844, U10 CA033601, CA-35195, U10 CA037404, U10 CA035448, U10 CA063848, U10 CA035195, CA-35103, CA-25224, N01 CA063844, CA-35113, U10 CA035101, U10 CA035113, P30 CA015083, CA-63848, U10 CA035415, U10 CA063849, CA-35415, U10 CA035431, CA-35269, CA-35448, CA-35101, U10 CA025224, CA31946, U10 CA063844, CA-63849, U10 CA035103  
Corr. Author:
 
Authors:
                     
Networks:
 
Study
NCCTG-N08CB
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
Gic5, Psc2, Psc5, Cmpl4, ORIGINAL REPORTS, Rapid Communications